Team Rhovac

With a Passion for Results

Team RhoVac features people with significant experience of pharmaceutical development as well as of business development and commercialisation. The team is driven by a deeply felt desire to create new and innovative cancer therapy for the benefit of patients. RhoVac is also well connected to external experts, which significantly aid the further development of the company. With founders, management and internal as well as external experts all working together in an open and engaged manner, the company is able to progress effectively, efficiently and with a steady focus.


Steven Glazer | Medical Director

Glazer has more than 30 years of experience from the pharma, diagnostic and biotech industries in Europe and in the USA. Glazer has a significant clinical experience both as operational leader and as project leader, spanning from preclinical to commercial areas.

Ann Christine Korsgaard | Regulatory Affairs

Korsgaard has more than 20 years of experience from pharma and biotech, and she has significant regulatory experience both in operational and in management roles. Korsgaard has substantial experience in interacting with EMA, FDA, PMDA (Japan) as well as with other national regulatory authorities.

Malene Weis | Clinical Coordinator

Weis has more than 20 years of clinical experience in pharma and biotech, both in operational and management roles. Weis also has previous clinical experience in developing cancer vaccines per se.

Alexandra Ellervik | PR, Communication & IR

Ellervik has an MSc in molecular biology and a PhD in neurophysiology. She has substantial experience in business development and project management both in academia and in business life.

Andrew Stone | MSc. Biostatistician

Stone has an MSc in Medical Statistics and he has more than 25 years of experience in pharma and biotech including more than 20 years of experience in clinical development and regulatory in the oncology area specifically. In addition, he has published several articles on biostatistics in peer review press.